Ovarian Cancer Clinical Trial
Official title:
TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WITH HIGH DOSE ETOPOSIDE AND CARBOPLATIN PLUS ESCALATING DOSE CYCLOPHOSPHAMIDE, FOLLOWED BY HEMATOPOIETIC RESCUE USING AUTOLOGOUS CD34+ SELECTED BLOOD STEM CELLS: A PILOT STUDY
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were
destroyed by chemotherapy used to kill tumor cells. Drugs used in chemotherapy use different
ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy
with peripheral stem cell transplantation may allow the doctor to give higher doses of
chemotherapy drugs and kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of cyclophosphamide
when given together with combination chemotherapy and a peripheral stem cell transplant in
treating patients with malignant solid tumors.
OBJECTIVES:
- Determine whether autologous transplantation of mobilized CD34+ peripheral blood stem
cells (PBSC) can provide complete hematologic reconstitution after myeloablative
chemotherapy comprising etoposide (VP-16) and carboplatin (CBDCA) in patients with
metastatic or recurrent rhabdomyosarcoma, neuroblastoma, Ewing's sarcoma/primitive
neuroectodermal tumor, germ cell tumors, childhood brain tumors, or hepatoblastoma.
- Determine the frequency and yield of CD34+ PBSC and granulocyte-macrophage
colony-forming units (GM-CFU) that are mobilized, harvested, and purified after a single
priming course of high-dose cyclophosphamide (CTX) followed by filgrastim (G-CSF).
- Correlate the number of CD34+ cells and GM-CFU in the autologous PBSC graft with time to
engraftment of white blood cells, neutrophils, and platelets in these patients.
- Determine the optimal day of PBSC harvest after a single priming course of high-dose CTX
and G-CSF in these patients.
- Determine whether CD34+ PBSC rescue and daily post-transplantation G-CSF decrease the
time to hematopoietic recovery after high-dose VP-16 and CBDCA compared to historical
results achieved in similar patients rescued with bone marrow.
- Compare the tumor cell content of marrow, mobilized blood, and purified CD34+ PBSC graft
preparations.
- Determine the optimal timing of PBSC mobilization and harvest in relation to extent of
prior chemotherapy in these patients.
- Determine the feasibility of a single leukapheresis for PBSC harvest in children.
- Determine the toxic effects of this regimen in these patients.
- Determine the antitumor activity of this regimen in these patients.
OUTLINE: This is a dose-escalation study of cyclophosphamide.
Mobilization/harvest: Patients receive cyclophosphamide IV over 90 minutes on day 0 and
filgrastim (G-CSF) subcutaneously or IV over 30 minutes on days 2-15 or until blood counts
recover. Peripheral blood stem cells (PBSC) are harvested and selected for CD34+ cells on day
15. Bone marrow is also harvested in case insufficient PBSC are harvested.
Preparative regimen/transplantation: Patients receive carboplatin IV over 1 hour and
etoposide IV continuously on days -6 to -4. Cyclophosphamide is administered IV over 1 hour
on days -3 and -2 or IV continuously on days -3 and -2, -4 to -2, -5 to -2, or -6 to -2. PBSC
or bone marrow is reinfused on day 0.
Cohorts of 3-10 patients receive escalating doses of cyclophosphamide until the maximum
tolerated dose (MTD) is determined. The MTD is defined as the highest dose at which 20% of
patients experience dose-limiting toxicity.
At least 6 additional patients receive cyclophosphamide at the MTD.
PROJECTED ACCRUAL: A minimum of 36 patients will be accrued for this study.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |